Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80,155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis.
Deng H, Zhao Y, Cai X, Chen H, Cheng B, Zhong R, Li F, Xiong S, Li J, Liu J, He J, Liang W. Deng H, et al. Among authors: zhao y. Crit Rev Oncol Hematol. 2022 Feb;170:103582. doi: 10.1016/j.critrevonc.2022.103582. Epub 2022 Jan 11. Crit Rev Oncol Hematol. 2022. PMID: 35031441 Review.
Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
Wang M, Liang H, Wang W, Zhao S, Cai X, Zhao Y, Li C, Cheng B, Xiong S, Li J, He J, Liang W. Wang M, et al. Among authors: zhao y, zhao s. Cancer. 2021 Mar 1;127(5):777-786. doi: 10.1002/cncr.33270. Epub 2020 Oct 29. Cancer. 2021. PMID: 33119182 Free article.
80,155 results
You have reached the last available page of results. Please see the User Guide for more information.